tbuckley/cabot-search huggingface dataset:
What the educators are saying
Authors: Phil Cotton, Jill Morrison
Journal: BMJ (2006)

How much does it matter if students sitting clinical examinations, or being interviewed for medical school, are told about the content of the assessment by fellow students? Concern about “breaches of security” leads assessors to go to extreme lengths, such as keeping groups of candidates apart or frequently changing the content of the assessment. This may not be necessary. Three studies conducted at McMaster University, Canada, looked at the effect of defined violations of test security in a multiple mini-interview process on the outcome of student admissions. The first “leak” by a student about one of the tests was posted on a website within seven minutes of completing the test. Nevertheless, the authors found no differences in performance between students who had been informed by peers and those who had not. Medical Education 2006;40: 36–42 [OpenUrl][1][PubMed][2] A medical student addresses the thorny problem of the cynicism that affects students as they progress through their studies. This … [1]: {openurl}?query=rft.jtitle%253DMedical%2Beducation%26rft.stitle%253DMed%2BEduc%26rft.aulast%253DReiter%26rft.auinit1%253DH.%2BI.%26rft.volume%253D40%26rft.issue%253D1%26rft.spage%253D36%26rft.epage%253D42%26rft.atitle%253DThe%2Beffect%2Bof%2Bdefined%2Bviolations%2Bof%2Btest%2Bsecurity%2Bon%2Badmissions%2Boutcomes%2Busing%2Bmultiple%2Bmini-interviews.%26rft_id%253Dinfo%253Apmid%252F16441321%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=16441321&link_type=MED&atom=%2Fbmj%2F332%2F7547%2F972.atom
ROENTGEN-RAY CASUALTIES.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Feasibility and impact on resectability of FOLFIRINOX in locally-advanced and borderline pancreatic cancer.
Authors: Fabienne Portales, Benedicte Gagniard, Simon Thezenas, Emmanuelle Samalin, Eric Assenat, Mathias Alline, Pierre-Emmanuel Colombo, Philippe Rouanet, Sebastien Carrere, François Quenet, Olivier Riou, Carmen Llacer, Thibault Mazard, Marc Ychou
Journal: Journal of Clinical Oncology (2016)

318 Background: Pancreatic cancer (PC) has a poor prognostic. Only patients who undergo a complete R0 surgery have longer survival rates. Treatment of locally-advanced (LA) and borderline (BL) PC is controversial. Folfirinox is considered as a standard first-line treatment in metastatic patients. The aim of our study was to evaluate the impact of Folfirinox in LA and BL PC. Methods: We performed a retrospective analysis of prospectively-collected data from LA and BL PC patients treated with original Folfirinox in our institution between January 2010 and February 2015. Results: 35 patients were enrolled, 20(57.1%) pancreatic head adenocarcinoma, 19(54.3%) LA and 16(45.7%) BL PC, 54.3% male, median age 60 years old [44-74]. OMS was 0, 1, 2 for 21(61.8%), 11(32.4%), 2(5.9%) patients. Median CA19.9 level was 5N [1-33]. All patients had Folfirinox in first-line followed by radiochemotherapy (RTCT) in 23(65.7%) patients, with Gemzar and Xeloda in 21 and 2 patients. Median number of chemotherapy cycles was 4 [1-13]. The grade 3-4 toxicity rate was 17.1% (n = 6), mainly digestive (67%), hematologic (16.7%), none neurologic. There was no toxic death. 17(46%) patients underwent surgery, 7 LA and 10 BL, with a R0 resection in 13 patients, mainly 8 PT3 (57.1%), no PT0, and 14N+. The morbidity rate was 40%, including 3 fistulae and 2 hemorrhages. Median overall survival was 24 months (95%CI:14-44), 53 (95%CI:26-.) and 12 months (95%CI: 9-19) in surgery versus no-surgery patients (p&lt; 0.001). Progression-free survival was 13.9 months (95%CI:11.2-17.1), 16.2 (95%CI:13.7-25.3) and 9.5 (95%CI:7.4-15.9) months in surgery versus no-surgery patients. 13 patients were still alive at the time of analysis, with a median follow-up of 44 months (95%CI:7-53). 30 patients had disease progression, locally, distant or both in 7(24.1%), 20(69.0%) and 3(13.1%) patients. Weight loss, OMS status, abdominal pain and CA199 level at diagnosis were not correlated with better survival. Conclusions: Folfirinox, followed or not by RTCT, as inductive treatment for LA and BL PC is feasible with acceptable toxicity, and allowed resectability in 37.1% patients, and thus a longer survival. Further studies are needed to confirm these encouraging results.
The Doctor's PDA and Smartphone Handbook: Medical References
Authors: Mohammad Al-Ubaydli, Chris Paton
Journal: Journal of the Royal Society of Medicine (2006)

This is the fourth in a series of extracts from a forthcoming book by M Al-Ubaydli and C Paton. The website [ www.rsmpress.co.uk/bkpda.htm ] includes video tutorials to accompany this text.
ON EARTH PEACE
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Occipito-Posterior Position: Its Mechanism and Treatment with a New Conception of the Rôle of the Pelvic Floor.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 173: Protein Kinase Cϵ Inhibits Vascular K <sub>Atp</sub> Channels By Caveolae-dependent Mechanism
Authors: Jundong Jiao, Vivek Garg, Baofeng Yang, Keli Hu
Journal: Circulation (2007)

Vascular ATP-sensitive K + (K ATP ) channels are critical regulators of arterial tone, thus blood flow in response to local metabolic needs. They are important targets for clinically used drugs to treat hypertensive emergency and angina. It is well known that protein kinase C (PKC) activation inhibits K ATP channels in vascular smooth muscles. However, the mechanism by which PKC inhibits the channel remains unknown. Since the K ATP channel pore-forming subunit Kir6.1 has been localized in caveolar microdomains of arterial smooth muscles, we tested the hypothesis that PKC-induced inhibition of vascular K ATP channels is through caveolae-dependent mechanism. The effect of caveolae/caveolin on PKC-mediated inhibition of recombinant K ATP channels was investigated in HEK293 cells transfected with Kir6.1 and SUR2B. As expected, whole-cell K ATP current density was significantly reduced by activation of PKC with phorbol-12-myristate-13-acetate (PMA, 1μM), but not its inactive congener 4α-PMA (1 μM). The PMA effect was prevented by application of PKCϵ inhibitor peptide Myristoylated PKCϵ V1–2 (Myr PKCϵ V1–2, 200 μM). Interestingly, the inhibitory effect of Myr PKCϵ V1–2 on K ATP channels was significantly reduced by disrupting caveolae with cholesterol-depleting agent methyl-β-cyclodextrin (10 mM, 51.9 ± 10.2% vs. 17.2 ± 5.6%, p&lt;0.01, n=5), and further enhanced by overexpression of caveolin-1 (36.8 ± 4.3% vs. 68.3 ± 8.5%, p&lt;0.05, n=5), indicating that integrity of caveolae is essential for PKC-dependent inhibition of K ATP channels. Further, Kir6.1 was localized in caveolar fraction by detergent-free sucrose gradient centrifugation. Immunofluorescence images showed that there was substantial colocalization between Kir6.1 and caveolin-1 on the sarcolemmal membrane as punctuate staining pattern. We also show that an antibody against caveolin-1 co-immunoprecipited Kir6.1, suggesting that Kir6.1 and caveolin-1 exist together in a complex. These results indicate that PKC-induced K ATP channel inhibition by PMA occurs within caveoar lipid raft microdomains. This study provides first evidence of caveolae-dependent mechanism involved in PKC-mediated K ATP channel modulation. Further studies in arterial smooth muscles are under investigation.
WRITES OF MUCH TROUBLE, BUT IS NOT DISCOURAGED.
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A comparative study of monoclonal antibody against EGFR (nimotuzumab) used in combination with chemoradiation versus chemoradiation alone in the treatment of locally advanced inoperable squamous cell carcinoma of the head and neck.
Authors: Aseem Rai Bhatnagar, Dharam Pal Singh, Rameshwaram Sharma, Om Prakash Sharma, Shantanu Sharma, Shivani Gupta, Prashant Kumbhaj
Journal: Journal of Clinical Oncology (2012)

e16012 Background: To determine the efficacy, safety and tolerability of concurrent Nimotuzumab (monoclonal antibody against epidermal growth factor receptor) used in combination with chemoradiation versus chemoradiation (CRT) alone in advanced inoperable squamous cell carcinoma of the head and neck (SCCHN). Methods: 56 patients were randomly assigned to either of the two treatment arms, nimotuzumab + CRT arm and CRT alone arm. Both arms received concurrent cisplatin 30 mg/m 2 repeated weekly for 6-7 cycles along with external beam radiotherapy 64-70 Gy (200cGy/day for 5 days a week for 6-7 weeks). Nimotuzumab arm additionally received nimotuzumab 200 mg weekly for 6-7 cycles. The patients were followed for 6 months after completion of CRT. The study end points were tumor response evaluation according to the RECIST Criteria version 1.1 and safety analysis using RTOG Acute Radiation Morbidity Scoring Criteria. Patients were evaluated weekly with hematologic tests and for adverse events like mucositis and dermatitis during the CRT. Tumor assessment was performed with clinical and endoscopic methods regularly during the CRT and then at 1 month, 3 month and 6 month interval after CRT. One MR imaging was done before starting the CRT to evaluate the baseline tumor characteristics and another was done after the completion of CRT either at 3 months or 6 months or at both the intervals. Results: 25 patients each were evaluable in both the arms who completed the 6 months study. The overall response rate (complete response + partial response) was 96% in Nimotuzumab + CRT arm whereas it was only 72% in CRT alone arm after 6 months of completion of CRT, which is statistically significant (p-value = 0.0206 by chi square test). Additionally, nimotuzumab did not potentiate toxicities of CRT and there was no significant difference in the acute radiation mucositis, dermatitis or hematological toxicities in both the groups (p-value&gt;&gt;0.05). Conclusions: Nimotuzumab can be safely added to the standard CRT treatment for advanced inoperable SCCHN, to achieve better tumor response without potentiating toxicity.
Long-term patient and graft survival after liver transplantation for autoimmune hepatitis
Authors: Melina Heinemann, René Adam, Marina Berenguer Haym, Darius F. Mirza, Seyed Ali Malek-Hosseini, John G. O’Grady, Ernest Hidalgo, Johann Pratschke, Karim Boudjema, Andreas Paul, Krzysztof Zieniewicz, Jiri Fronek, Karl Heinz Weiss, Vincent Karam, Christophe Duvoux, Ansgar Lohse, Christoph Schramm
Journal: Journal of Hepatology (2020)
Returning Astronaut Study Helps Some Reeling Patients
Authors: M. Mitka
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reversal of hemiballismus by tetrabenazine
Authors: J. Pearce
Journal: JAMA (1972)

<h3>To the Editor.—</h3> Recent advances in knowledge of cerebral monoamines have increased our understanding of the mechanisms of the extrapyramidal disorders, notably parkinsonism.<sup>1-3</sup>The cause of the diverse involuntary movements seen in striatal and related diseases remains incompletely explained, except for the probable if unproved hypothesis that both levodopa-induced and phenothiazine dyskinesias reflect an increase in dopaminergic activity or enhanced sensitivity of the striatal neurones. Hemiballismus (hemichorea) is perhaps the most striking and gross example of involuntary movements with relatively less alteration of tone and posture than is commonly seen in basal ganglia disorders. In a series of papers between 1927 and 1961, Purdon Martin<sup>4-6</sup>described a number of well-documented clinicopathological studies of this disorder, and established that a hemorrhage, infarct, and, rarely, other pathological processes of the corpus Luysii, in the presence of an intact pallidofugal system, were the responsible lesions. With reference to the work of
Targeted expression of a human pituitary tumor–derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis
Authors: Shereen Ezzat, Lei Zheng, Xian-Feng Zhu, Gillian E. Wu, Sylvia L. Asa
Journal: Journal of Clinical Investigation (2015)

An investigation by the University Health Network recently found that portions of the RT-PCR gels shown in Figure 1, B (PGK-1 panel) and C (FGFR1 panel), are duplicated in this publication and in a subsequent publication (1).The samples were labeled differently in the panels, and the marker was shifted in Figure 1B.The corresponding author has indicated that other data from the initial screen of these samples support the conclusions made in the paper; however, the original data for the RT-PCR gels shown in Figure 1 are no longer available.The JCI's policies prohibit data manipulation and data duplication.Therefore, the JCI is retracting this article.No issues have been raised in regard to any of the other data in this manuscript.
Error in Figure
Journal: JAMA Network Open (2020)

Priya Vart, PhD; Neil R. Powe, MD, MPH, MBA; Charles E. McCulloch, PhD; Rajiv Saran, MD; Brenda W. Gillespie, PhD; Sharon Saydah, PhD; Deidra C. Crews, MD, ScM; for the Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team
Abstract LB-042: High ITGB1 &amp; RhoC expressions are indicators of recurrence in patients with primary colorectal cancer
Authors: Ye Jin Ha, Ka Hee Tak, Chan Wook Kim, Jong Ryul Lee, Dong-Hyung Cho, Yong Sung Kim, Seon-Kyu Kim, Jin Cheon Kim
Journal: Cancer Research (2019)

Abstract Colorectal cancer (CRC) is the main cause of cancer mortality worldwide. Its poor prognosis is mainly ascribed to high recurrence rates. Identifying novel prognostic biomarkers and therapeutic key points for management is crucial and important. To develop prognostic biomarkers that can discriminate CRC patients with high risk of postoperative recurrence, we conducted RNA-seq analysis using primary cancer tissues from 130 CRC patients with (n=58) or without (n=72) systemic recurrence. Among differentially expressed genes between with or without recurrence, we identified eleven candidate genes (AK2, BID, CDC25A, EIF4A2, HSPB1, ITGB1, MAP4K4, MMP12, PTGES3, RHOC, TERF21P) (P &amp;lt; 0.01). Then, the expression level of the best candidate gene was validated by quantitative real-time polymerase chain reaction (qRT-PCR) in the additional 79 CRC patients with (n=40) or without (n=39) systemic recurrence. Among these genes, qRT-PCR showed that AK2, EIF4A2, ITGB1 and RhoC were upregulated. To the relevance of their molecular function and biological process, Cell Counting Kit-8 assay, migration, invasion assay and gelatin zymograpy were performed after knockdown or overexpression of candidate genes in CRC cell lines. ITGB1 or RhoC stimulated colon cancer cell proliferation, promoted cell invasion and migration, whereas the opposite pattern was observed in ITGB1 or RhoC-overexpressing CRC cells. Western blotting experiments revealed that ITGB1 and RhoC overexpression downregulated E-cadherin and upregulated N-cadherin, Snail/Slug, Vimentin protein levels, whereas ITGB1 and RhoC knockdown had the opposite effects These results suggested that ITGB1 and RhoC promoted colon cancer cell proliferation, migration and invasion through EMT switch signaling pathway. Our results indicate that ITGB1 and RhoC may be biomarkers to predict recurrence and future therapeutic targets of CRC. Citation Format: Ye Jin Ha, Ka Hee Tak, Chan Wook Kim, Jong Ryul Lee, Dong-Hyung Cho, Yong Sung Kim, Seon-Kyu Kim, Jin Cheon Kim. High ITGB1 &amp; RhoC expressions are indicators of recurrence in patients with primary colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-042.
Medical News
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Extrinsic sugar as vehicle for dietary fat
Authors: AndrewM Prentice, SusanA Jebb, AlisonE Black, M.J Gibney, C Bolton-Smith, J.I Macdiarmid, J.E Cade, J.E Blundell, K.W Heaton, P.M Emmett, Kei Kudo, Toshiko Saito, Yumi Sano
Journal: The Lancet (1995)